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Background: HRQL in IPF patients is impaired. Data from other respiratory diseases led us to
hypothesize that significant gender differences in HRQL in IPF also exist.
Methods: Data were drawn from the NIH-sponsored Lung Tissue Research Consortium (LTRC).
Demographic and pulmonary physiology data along with MMRC, SF-12, and SGRQ scores from
women vs. men were compared with two-sample t-tests. Multivariate linear regression was
used to examine the association between SF-12 component scores and gender while adjusting
for other relevant variables.
Results: The study sample consisted of 147 men and 74 women. Among several baseline vari-
ables, only DLCO% predicted differed between women and men, (43.7 vs. 38.0, pZ 0.03). InCOPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity for carbon monoxide; FVC,
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Gender influences health-related Quality of Life in IPF 725general, men exhibited lower (better) MMRC scores (1.7 vs. 2.4, pZ 0.02), particularly those
with milder disease as measured by DLCO% predicted. In an adjusted analysis, SF-12 PCS scores
in men were lower (worse) than women (pZ 0.01), an effect that was more pronounced in
men with greater dyspnea scores. In a similar analysis, SF-12 MCS scores in women were lower
than men (worse) (48.3 vs. 54.4, pZ 0.0004), an effect that was more pronounced in women
with greater dyspnea scores.
Conclusions: Significant gender differences in HRQL exist in IPF. As compared to women, men
reported less severe dyspnea, had worse SF-12 PCS scores, but better SF-12 MCS scores. Dys-
pnea appears to have a greater impact on the physical HRQL of men and the emotional HRQL
of women. An improved understanding of the mechanism behind these differences is needed to
better target interventions.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common
form of idiopathic interstitial pneumonia.1 In fact, preva-
lence estimates are on the rise and are predicted to
continue to increase.2 The clinical course of IPF tends to be
progressive and mortality is high. Consequently, IPF
patients, like many others with other debilitating, life-
shortening diseases, have impaired Quality of Life (QOL).
Because there is no effective pharamacologic therapy
proven to slow decline in pulmonary function or reduce
mortality, IPF patients (and the practitioners caring for
them) often focus on attempting to maintain or improve
their QOL. IPF profoundly impairs a patients’ sense of well-
being, but relatively few studies have examined QOL or
health-related QOL (HRQL) e defined here as an individu-
al’s perception of the impact of health on his or her QOL e
in this patient population. A recent systematic review of
HRQL in IPF found only seven studies (with a total of 512
patients) meeting rigorous inclusion criteria.3 Only a few
studies have examined longitudinal changes in HRQL in IPF,
but each reports worsening HRQL over time.4,5 No studies
have examined differences in HRQL or symptoms between
male and female patients with IPF.
In chronic obstructive pulmonary disease (COPD), it is
clear that men and women differ in a number of
aspects.6,7 Female COPD patients are more likely than
males to report severe dyspnea, and on balance, females
have worse HRQL than men.8 Female COPD patients suffer
higher levels of anxiety and depression than their male
counterparts which could contribute to HRQL discrep-
ancies.9,10 Finally, disease status does not predict the
presence or intensity of symptoms in females with COPD
as well as it does in males.11 Only recently have investi-
gators begun to systematically explore differences in
disease behavior between female and male IPF patients. It
is well-established that women are less prone to develop
IPF than men (although the number of women with IPF
appears to be rising at a steeper rate than men,2 but the
observations that women have better survival and expe-
rience less rapid progression of disease than men are
new.12 In this study, we aimed to further examine
differences between female and male IPF by focusing on
HRQL and dyspnea. We hypothesized that HRQL would be
more impaired and dyspnea would be more severe among
women than men.Methods
The study sample was identified through the multi-center
Lung Tissue Research Consortium (LTRC) (http://www.
ltrcpublic.com). The LTRC is a tissue bank sponsored by
the National Heart Lung and Blood Institute that began
sample collection in 2003. The two primary groups of
patients on whom the LTRC collects data include COPD and
interstitial lung disease (ILD); the majority of data are from
patients with IPF. Prior to specimen procurement, all LTRC
subjects undergo an extensive, standardized, pre-operative
phenotypic evaluation which includes demographics,
detailed occupational history, complete pulmonary func-
tion testing and a standardized chest CT scan. A final clin-
ical diagnosis of IPF was assigned based on currently
accepted international consensus guidelines.13 All subjects
with a final clinical diagnosis of IPF at the time of data
query were included in this analysis (221 of the 1400
enrolled at the time of data query in February 2009). Each
subject included in this analysis underwent diagnostic
surgical lung biopsy or lung transplant as part of their
clinical care for IPF. Subjects with an alternative diagnosis
on pathological evaluation were excluded. All subjects
provided written informed consent, and the institutional
review board at each institution approved the study.Clinical assessment
Demographic data, smoking and medical history, along with
dyspnea and HRQL assessments were collected via self-
administered questionnaires prior to biopsy or transplant.
Dyspnea was quantified using the modified Medical
Research Council dyspnea scale (MMRC)14 which is a five-
point scale that asks respondents to rate dyspnea from
0 (absent) to 4 (dyspnea when dressing/undressing). The
MMRC has previously been used to evaluate dyspnea in IPF
patients; its scores correlate with HRQL15 and predict
survival.16 General HRQL was assessed with the SF-12
version 2. The SF-12 taps the same eight domains as the
SF-36 and like the SF-36, it also has two psychometrically-
derived primary subscales, the physical and mental health
composite scores (PCS and MCS). Scores from the SF-12 and
each primary subscale range from 0-100, with higher scores
indicating better HRQL. The SF-12 is a shorter alternative to
the SF-36 which has accepted validity in IPF.4,17 Multiple
Table 2 Comparison of mean SF-12, MMRC, SGRQ scores.
Men (SD) Women (SD) p-value
MMRC (median) 2 3 0.02
SF-12 PCS 35.6 (12.5) 37.7 (9.9) 0.21
Physical functioning 34.1 (12.2) 32.7 (10.8) 0.40
Role-physical 37.7 (13.0) 36.8 (12.6) 0.62
Bodily pain 49.2 (11.8) 49.0 (10.4) 0.88
General health 39.4 (13.3) 42.2 (11.7) 0.13
SF-12 MCS 54.4 (9.7) 48.3 (12.2) 0.0004
Vitality 45.9 (11.6) 44.6 (11.1) 0.42
Social functioning 47.6 (11.3) 43.9 (12.8) 0.05
Role-emotional 48.1 (11.4) 41.9 (14.1) 0.002
Mental health 53.0 (8.9) 47.8 (10.8) 0.0007
Total SGRQ score 44.6 (23.6) 48.2 (20.1) 0.27
Activity subscore 57.7 (30.3) 75.3 (24.3) 0.05
Impacts subscore 35.2 (22.7) 37.6 (21.9) 0.39
Symptoms subscore 49.7 (25.0) 48.9 (20.3) 0.81
726 M.K. Han et al.studies, however, have documented the comparability of
the SF-12 to the SF-36 in different diseases.18,19 For each
domain and summary component, we used scoring algo-
rithms to generate linear T-score transformations to place
scores on scales with mean scores equal to 50 and standard
deviations of 10. Saint George’s Respiratory Questionnaire
(SGRQ) is an obstructive lung disease-specific question-
naire, with three domains, all scored from 0 to 100. Higher
scores correspond to worse HRQL.20 The SGRQ appears to
possess longitudinal validity in IPF.17
Physiologic testing
Spirometry before and after the administration of albuterol
and DLCO were measured according to American Thoracic
Society guidelines. The 6-min walk test was completed
using a modification of a previously published protocol.21
The average length of time between clinical assessment
and physiologic testing was approximately 1 day.
Statistical analysis
All analyses were completed by using SAS statistical soft-
ware, version 9.1 (SAS Inc., Cary, NC). Baseline character-
istics, SGRQ, and SF-12 data were compared between
genders by using two-sample Student’s t-tests. Because the
MMRC data were skewed, a Wilcoxon rank sum test was
used to compare MMRC scores between genders. Multivar-
iate linear regression was used to examine the association
between gender (independent variable) and either HRQL or
MMRC scores (dependent variables) while adjusting for age,
FVC and DLCO% predicted, body mass index (BMI), and
smoking. Because each of these candidate variables could
potentially confound the association between gender and
HRQL or MMRC scores, we elected not to perform univariate
analyses and included all of them in each multivariate
model. No adjustment was made for multiple comparisons,
thus it is possible that one in 20 comparisons based on
a cutoff of p < 0.05 may be spuriously statistically
significant.
Results
The study sample consisted of 147 men and 75 women.
Demographics are outlined in Table 1. Men and women
were of similar average age (63.3 years for men vs.
62.3 years for women, pZ 0.44). There was no significant
difference between men and women in baseline FVC%Table 1 Demographics by gender.
Men
nZ 147 (SD)
Women
nZ 74 (SD)
p-value
Age in years 63.3 (8.2) 62.3 (9.9) 0.44
FVC% predicted 62.1 (16.8) 64.4 (18.7) 0.36
DLCO% predicted 38.0 (14.8) 43.7 (17.9) 0.03
BMI 29.6 (5.1) 30.8 (5.3) 0.14
Cigarette pack years 23.3 (13.3) 22.2 (11.3) 0.65
Walk distance
(meters)
365.8 (136.2) 347.9 (109.1) 0.34predicted (62.1 men vs. 64.4 women, pZ 0.36), but
women had slightly higher DLCO% predicted than men (38.0
men vs. 43.7 women, pZ 0.03). No significant difference
was observed in 6-min walk distance between genders
(mean 365.8 m men vs. 347.9 m women, pZ 0.34), and
there was no significant difference between genders in BMI
or cigarette pack years.
Results for between gender comparisons for MMRC, SF-
12 and SGRQ are displayed in Table 2. MMRC scores were
significantly better (lower) in men vs. women median score
2 for men and 3 for women (pZ 0.02). Because of differ-
ences in DLCO% predicted between groups, the possibility of
a gender-DLCO interaction was explored in multivariate
models for MMRC. Figure 1 shows the relationship between
DLCO% and gender for the MMRC outcome (pZ 0.02 for
gender-DLCO interaction). No significant difference in
unadjusted SF-12 PCS scores were observed between
genders; however, the SF-12 MCS score was significantly
better (higher) in men than women (54.4 men vs. 48.3
women, pZ 0.0004). Social functioning, role-emotional,
and mental health domain scores were also better for men
than women while the other MCS and PCS subdomainsFigure 1 Graphical relationship between DLCO% predicted
and MMRC demonstrating more dyspnea in women than men at
higher levels of DLCO% predicted.
Figure 2 Graphical relationship between SF-12 PCS score
and MMRC demonstrating worse PCS scores in men than women
with greater dyspnea.
Gender influences health-related Quality of Life in IPF 727showed no significant gender difference. No significant
difference in total SGRQ score was seen, although the
activity score was better (lower) for men than women (57.7
men vs. 75.3 women, pZ 0.05).
Results of multivariate analyses for predicting SF-12 PCS
scores are shown in Table 3. After correcting for lung
function, functional capacity (as measured by 6MWD), and
other important potential predictors, female gender was
associated with higher (better) scores (pZ 0.01). Longer
6MWD (pZ 0.002) and lower MMRC score (pZ 0.04) were
also associated with higher SF-12 PCS scores. For the PCS
outcome variable, a significant MMRC-gender interaction
was detected (pZ 0.009) that is graphically displayed in
Figure 2.
Results of multivariate analyses for predicting SF-12 MCS
scores are also shown in Table 3. Here, after correcting for
lung function, functional capacity (as measured by 6MWD),
and other important potential predictors, female gender
was associated with lower (worse) MCS scores (pZ 0.008).
Higher BMI and lower MMRC were also associated with
better MCS scores (pZ 0.04 and pZ 0.05, respectively). A
significant MMRC-gender interaction was also detected for
SF-12 MCS (pZ 0.004), graphically displayed in Figure 3. No
significant gender differences were observed in multivar-
iate analyses (adjusted for the same predictors as SF-12
analyses) for SGRQ total or subscores (data not shown).
Discussion
Prior data suggest that HRQL in IPF patients as assessed by
the SF-36 (similar to the SF-12), SGRQ and other instru-
ments is impaired in multiple domains, but particularly
domains tapping physical functioning, symptoms, and level
of independence.3 Work by others also suggests that dysp-
nea, as measured by the MMRC or other scales, correlatesTable 3 Multivariate model SF-12.
PCS Parameter 95% CI p-value
Intercept 44.54 25.54, 63.56 <0.0001
Female gender 5.17 1.23, 9.10 0.01
Age in years 0.07 0.25, 0.12 0.48
FVC% 3.80 17.03, 9.44 0.57
DLCO% 2.52 17.09, 12.04 0.73
Cigarette pack years 0.07 0.20, 0.05 0.25
BMI 0.06 0.42, 0.31 0.77
Walk distance
in meters
0.03 0.01, 0.04 0.002
MMRC 4.39 5.84, 2.94 0.04
MCS
Intercept 51.37 28.41, 74.32 <0.0001
Female gender 6.61 1.80, 11.42 0.008
Age in years 0.07 0.15, 0.29 0.53
FVC% 4.31 20.51, 11.87 0.60
DLCO% 5.23 23.05, 12.59 0.56
Cigarette pack years 0.13 0.28, 0.03 0.10
BMI 0.57 0.02, 0.92 0.04
Walk distance
in meters
0.006 0.03, 0.01 0.52
MMRC 1.79 3.56, 0.008 0.05strongly with HRQL scores in IPF.15,22 In COPD men and
women differ in their symptom intensity and degree of
HRQL impairment.6,7 Although very recent research has
shown improved survival and less rapid physiologic
progression for women with IPF as compared with men,12 no
study has examined whether these differences between
genders extend to HRQL or dyspnea in IPF.3 In the current
study, we observed significant differences in HRQL scores
between men and women. Data from U.S. general pop-
ulation norms show men score approximately 2.5 points
higher on the SF-12 PCS and just under 2 points higher on
the MCS compared with women.23 In contrast, in the
current study, in analyses adjusted for a number of clini-
cally important potential confounders, we observed that
female gender was associated with a higher PCS score (by 5
points). Furthermore, as expected, females had lower MCS
scores than males, but in an adjusted analysis, the differ-
ence we observed was over three times greater than
expected (6.6 points compared with just under 2 points for
population norms).Predicted SF12 MCS Score by Gender
Women
Men
SF
12
 M
CS
20
30
40
50
60
70
MMRC
0 1 2 3 4
Scale for MMRC 0-4 with higher scores indicating higher levels of dyspnea; scale for 
PCS 0-100 with higher scores indicating better health status. 
Figure 3 Graphical relationship between SF-12 MCS score
and MMRC demonstrating worse MCS scores in women than men
with greater dyspnea.
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in the case of milder IPF as defined by higher DLCO% pre-
dicted, there was discordant dyspnea perception between
genders. On balance, women reported more severe dysp-
nea than men. However, at lower levels of lung function (as
assessed by DLCO%), the gender gap closed. Between
genders, discordant dyspnea, as measured by the MMRC,
has also been reported in COPD.7 Neurobiological studies
demonstrate that women have a higher intrinsic sensitivity
than men to noxious somatic sensations, including dysp-
nea.24,25 Thus, it is possible that women are inherently
more keen to sense (and report) dyspnea at earlier stages
of IPF. An alternative explanation is that the female
subjects in this study were more physically fit and active
than the male subjects. Data required to examine this
possibility were not collected as part of this study, but the
absence of significant differences between genders in BMI
and 6MWD argue against this hypothesis. Regardless, as IPF
progresses and lung function becomes increasingly
impaired, both men and women will sense significant
dyspnea.
We also observed that, even after accounting for
differences in age, pulmonary physiology, functional
capacity, and other important predictors, there were
differences between genders in HRQL: males had more
impaired HRQL in physical health domains but less impaired
HRQL in mental health domains than females. Gender
differences in social roles could explain some of these
differences. Considering women frequently regard them-
selves as caregivers, it is possible that the emotional impact
of this disease may be different for them than for men.
Another possibility is that women may view the social
stigma of the disease, such as needing to wear supple-
mental oxygen, as more bothersome. Differences between
how men and women cope with chronic illness could
influence the emotional impact of a disease. Men tend to be
more proactive in trying to modify their environment when
confronted with significant challenges, such as health
problems; this could prove advantageous when dealing with
a disease such as IPF.26 Differences in socioeconomic or the
presence or type of comorbid conditions at the time of
diagnosis may also influence gender differences in HRQL.
We believe these possibilities merit further investigation.
The final novel observation from this study was that
among men, dyspnea appears to have a greater association
with physical HRQL domains than mental HRQL domains,
while among women, the impact of dyspnea is greater on
mental HRQL domains than physical HRQL domains. The
experience of dyspnea has sensory and affective dimen-
sions. It is associated not only with lung dysfunction, but
also with emotional responses to sensations, and higher-
order interpretations of these experiences (e.g., meaning)
which influence not only self-reports of dyspnea intensity
per se, but also the impact of dyspnea on patient physical
and emotional functioning. The greater impact of dyspnea
on emotional HRQL in women in our data is consistent with
findings from other studies in which investigators observed
greater emotional burden of chronic disease on women
than men. For example, women with COPD are more likely
to suffer from anxiety and depressive disorders.6 Clear
neurobiologic differences exist between men and women
both in their sensitivity and processing of noxious somaticsensations but also in the higher level processing and
interpretation of that information.27 Brain regions associ-
ated with the affective dimension of dyspnea have been
identified, but gender differences have not yet been
examined.
The average SGRQ activity score in ‘‘healthy’’ men has
been reported to be 12.17 vs. 14.58 for women.28 We
observed a much greater difference of approximately 18
points, although the difference was absent when we
adjusted for potential confounders. This is in contrast to
COPD where female patients have worse (higher) SGRQ
scores than males.8 As opposed to the SF-12, however, the
SGRQ is an obstructive disease-specific instrument that may
lack the sensitivity to capture gender differences in IPF.
This is a subject worthy of further investigation.
There are limitations to our study. While on average,
male and female subjects were similar and we adjusted for
multiple possible confounders including lung function and
6 min walk distance, we acknowledge that physiologic
measures of disease status are not the only significant
contributors to HRQL. We do not have data on length of
time since IPF diagnosis or any data on treatment. Differing
disease duration could influence dyspnea, one of the main
drivers of HRQL in IPF.3,22 Medications, such as oral gluco-
corticoids in particular29 or immune suppressing agents,
sometimes prescribed for patients with ILD, may cause
adverse effects that impact HRQL. Also lacking in our
dataset are other potentially meaningful variables that
could influence HRQL, including socioeconomic status and
comorbid physical or mental conditions. Finally, a question
that often arises in studies of HRQL is whether the selected
instruments are appropriate for assessing the population
under study. To our knowledge, the psychometric proper-
ties of the SF-12 have never been systematically examined
in IPF, but investigators of several recent studies have
reported that the SF-36 and SGRQ possess reasonable reli-
ability and both cross-sectional and longitudinal validity in
IPF.4,17 All SF-12 items are in the SF-36, and numerous
studies have demonstrated their comparability, hence it
can be reasonably assumed the SF-12 would perform similar
to the SF-36 in IPF as well. A strength of this study is the
very well-characterized patient population in which IPF was
diagnosed rigorously by multidisciplinary clinical, radio-
logical and pathological assessments.30,31 Furthermore, the
large variety of patients, ranging from those diagnosed with
surgical biopsy (milder disease) and those undergoing lung
transplantation (severe disease), provides a wide snapshot
of the IPF population.
In conclusion, it appears as though men with IPF have
less dyspnea, worse physical HRQL, but better emotional
HRQL than women with IPF. However, dyspnea more
profoundly impacts the physical HRQL of men and the
emotional HRQL of women. IPF differs from other chronic
respiratory diseases, particularly COPD, where women have
worse physical and worse mental HRQL than men, whether
assessed by the SF-36 or SGRQ.8,32 Up until recently, women
were frequently excluded from clinical research, particu-
larly therapeutic trials. The realization that men and
women might differ from biologic, social and psychologic
perspectives and that this could influence disease presen-
tation and progression has only of late become a topic of
discussion within the academic community. Future research
Gender influences health-related Quality of Life in IPF 729will need to incorporate gender differences in a way that
has previously not been explored, in IPF or otherwise.
Based on the analyses we present here, clinical trials in IPF
that seek to assess change in HRQL will need to take into
account the expected numbers of men and women to be
randomized and baseline differences that exist. Further
longitudinal data will be needed to determine whether
change in HRQL differs by gender so that these data can be
incorporated into clinical trial design as well. From the
standpoint of developing and testing therapies in IPF, our
data suggest drugs intended to improve exercise capacity or
dyspnea might impact HRQL in men and women differently.
Finally, our data suggest that if we seek to improve HRQL in
IPF, particularly in patients with severe disease, that men
may be in greater need of interventions that target physical
domains and women interventions that emotional domains
of HRQL.
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